Loading stock data…
PRTC
$18.14+0.89 (+5.16%)
Market ClosedLast close May 1
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
PureTech Health plc in the Healthcare sector is trading at $18.14. The stock is currently 9% below its 52-week high of $19.92, remaining 4.5% above its 200-day moving average. Technical signals show neutral RSI of 53 and bullish MACD crossover, explaining why PRTC maintains its current momentum and trend strength. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 53) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$18.14
Potential Upside
97.1%
Whystock Fair Value$35.75
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-20...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$434.50M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
10.50
Beta
Defensive asset. Lower volatility than the S&P 500.
0.71
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
13.48%
Volume
Today's trading volume
45,246
Recent News
PureTech Health shares boosted as investee Seaport Therapeutics prices Nasdaq IPO
PureTech Health (LSE:PRTC, NASDAQ:PRTC, OTC:PTCHF, FRA:0VQ) told investors that its founded entity Seaport Therapeutics has priced an upsized US initial public offering at the top of its target range, putting the clinical-stage neuropsychiatry company on course to raise gross proceeds of $254.9...
PureTech Health H2 Earnings Call Highlights
PureTech Health (NASDAQ:PRTC) used its annual results call to outline a refined operating strategy centered on a leaner corporate structure, earlier formation of “founded entities,” and an increased emphasis on returning capital to shareholders when significant inflows occur. Chief Executive Office
Psychiatry Drugmaker Seaport Seeks $212.4 Million in US IPO
(Bloomberg) -- Seaport Therapeutics Inc., a clinical-stage biotechnology company focused on antidepressants and anxiety drugs, is seeking to raise $212.4 million in a US initial public offering.Most Read from BloombergSergey Brin Confronted Gavin Newsom — Then Launched a Political WarThe Billion-Barrel Hormuz Oil Shock Is About to Crash DemandTrump Being ‘Humiliated’ in Iran Talks, German Leader SaysOpenAI Breaks Free From Exclusive AI Pact With MicrosoftThe $1 Million Retirement Myth: Here’s Wh
PureTech Health plc (LON:PRTC) is favoured by institutional owners who hold 73% of the company
Key Insights Significantly high institutional ownership implies PureTech Health's stock price is sensitive to their...
PureTech Health Completes End-of-Phase 2 Meeting With FDA for Deupirfenidone to Treat Idiopathic Pulmonary Fibrosis
PureTech Health (PRTC) said Monday that it completed the end-of-phase 2 meeting with the US Food and